189 related articles for article (PubMed ID: 19060922)
1. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C; Mueller D; Buhl S; Garcia-Cuellar MP; Slany RK
Oncogene; 2009 Feb; 28(6):815-23. PubMed ID: 19060922
[TBL] [Abstract][Full Text] [Related]
2. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
3. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.
Allen MD; Grummitt CG; Hilcenko C; Min SY; Tonkin LM; Johnson CM; Freund SM; Bycroft M; Warren AJ
EMBO J; 2006 Oct; 25(19):4503-12. PubMed ID: 16990798
[TBL] [Abstract][Full Text] [Related]
5. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).
Ono R; Taki T; Taketani T; Taniwaki M; Kobayashi H; Hayashi Y
Cancer Res; 2002 Jul; 62(14):4075-80. PubMed ID: 12124344
[TBL] [Abstract][Full Text] [Related]
6. Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.
Robert I; Aussems M; Keutgens A; Zhang X; Hennuy B; Viatour P; Vanstraelen G; Merville MP; Chapelle JP; de Leval L; Lambert F; Dejardin E; Gothot A; Chariot A
Oncogene; 2009 Apr; 28(13):1626-38. PubMed ID: 19219072
[TBL] [Abstract][Full Text] [Related]
7. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
8. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.
Cierpicki T; Risner LE; Grembecka J; Lukasik SM; Popovic R; Omonkowska M; Shultis DD; Zeleznik-Le NJ; Bushweller JH
Nat Struct Mol Biol; 2010 Jan; 17(1):62-8. PubMed ID: 20010842
[TBL] [Abstract][Full Text] [Related]
9. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.
García-Cuéllar MP; Zilles O; Schreiner SA; Birke M; Winkler TH; Slany RK
Oncogene; 2001 Jan; 20(4):411-9. PubMed ID: 11313972
[TBL] [Abstract][Full Text] [Related]
10. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
So CW; Lin M; Ayton PM; Chen EH; Cleary ML
Cancer Cell; 2003 Aug; 4(2):99-110. PubMed ID: 12957285
[TBL] [Abstract][Full Text] [Related]
11. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
12. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.
Birke M; Schreiner S; García-Cuéllar MP; Mahr K; Titgemeyer F; Slany RK
Nucleic Acids Res; 2002 Feb; 30(4):958-65. PubMed ID: 11842107
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for activity regulation of MLL family methyltransferases.
Li Y; Han J; Zhang Y; Cao F; Liu Z; Li S; Wu J; Hu C; Wang Y; Shuai J; Chen J; Cao L; Li D; Shi P; Tian C; Zhang J; Dou Y; Li G; Chen Y; Lei M
Nature; 2016 Feb; 530(7591):447-52. PubMed ID: 26886794
[TBL] [Abstract][Full Text] [Related]
14. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
[TBL] [Abstract][Full Text] [Related]
15. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
16. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.
Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
18. Human CpG binding protein interacts with MLL1, MLL2 and hSet1 and regulates Hox gene expression.
Ansari KI; Mishra BP; Mandal SS
Biochim Biophys Acta; 2008 Jan; 1779(1):66-73. PubMed ID: 18082152
[TBL] [Abstract][Full Text] [Related]
19. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
Ayton PM; Cleary ML
Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
